What happened
Shares of iBio (NYSEMKT:IBIO) climbed on Friday after the biotech announced plans to develop an intriguing second-generation vaccine candidate for COVID-19. By the close of trading, iBio's stock price was up 16.7% after rising as much as 41.3% earlier in the day.
So what
iBio's experimental vaccine, IBIO-202, targets the nucleocapsid protein (N protein) of the novel coronavirus. N proteins tend to produce an immune response and remain relatively unchanged during mutations. By targeting the N protein, iBio hopes to develop a vaccine that will be highly effective against new coronavirus variants.

Image source: Getty Images.
"The N protein strategy of IBIO-202 is complementary to existing first-generation, S protein-directed vaccines and may be suitable as a more universal coronavirus vaccine," iBios' chief scientific officer, Martin Brenner, said in a press release.
iBio used its plant-based FastPharming System to express N protein antigens and has begun preclinical studies, the results of which are expected in its fiscal 2022 first quarter.
Now what
iBio acknowledged that competition is intense in the COVID-19 vaccine space. Yet management correctly believes there is still room for new vaccines that can help to defend against emerging coronavirus strains. Thus, should IBIO-202 prove safe and effective in clinical trials, there would likely be strong global demand for iBio's new vaccine.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
"Here" - Google News
May 08, 2021 at 09:15PM
https://ift.tt/3hc9OpV
Here's Why iBio Stock Surged Friday - The Motley Fool
"Here" - Google News
https://ift.tt/39D7kKR
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
No comments:
Post a Comment